<DOC>
	<DOCNO>NCT01304563</DOCNO>
	<brief_summary>Intradermal influenza vaccination may result good efficacy compare intramuscular vaccination .</brief_summary>
	<brief_title>2010/2011 Trivalent Influenza Vaccination</brief_title>
	<detailed_description>This prospective , randomize , single centre trial Queen Mary Hospital . We aim recruit 400 subject [ minimum 50 subject per group ] would qualify Hospital Authority ( HA ) / Centre Health Protection ( CHP ) Mass Vaccination Program 2010/2011 TIV . These patient include elderly age 65 adult patient age 21 chronic illness ( healthcare worker ) . Subjects randomly assign 4 group : Group 1 ( ID1 ) receive single low-dose intradermal injection 2010/2011 TIV , microneedle device . Group 2 ( ID2 ) receive single high low-dose intradermal injection 2010/2011 TIV microneedle device . Group 3 ( IM15 ) receive single full-dose ( 15ug ) standard 2010/2011 TIV deliver intramuscularly conventional needle . Group 4 ( INT ) receive single low-dose intradermal injection 2010/2011 TIV , Intanza® needle . The 2010/2011 TIV use Fluzone® , Sanofi-Pasteur group 3 Intanza® , Sanofi-Pasteur group 1,2 4 .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>All participant qualify HA/ CHP Mass Vaccination Program TIV 2010/2011 seasonal influenza state : include elderly age 65 adult patient age 21 either healthcare worker chronic illness include hypertension , diabetes mellitus , ischemic heart disease , cerebrovascular disease , thyroid disease chronic renal failure . All patient give write informed consent . Subjects must available complete study comply study procedure . Clinically significant immunerelated disease , significant recent comorbidities pregnant volunteer . History illness might interfere result study pose additional risk subject due participation study Have know allergy egg component Study Vaccines ( include gelatin , formaldehyde , octoxinol , thimerosal , chicken protein ) , history anaphylaxis , serious vaccine reaction , excipients . Have immunosuppression result underlie illness treatment , use anticancer chemotherapy radiation therapy ( cytotoxic ) within precede 36 month . Have active neoplastic disease history hematologic malignancy . Have know active human immunodeficiency virus ( HIV ) , Hepatitis B , Hepatitis C infection autoimmune hepatitis cirrhosis . History progressive severe neurological disorder GuillainBarré Syndrome .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>